New Study: "Comparison of peritendinous hyaluronan injections versus extracorporeal shock wave therapy in the treatment of painful Achilles tendinopathy: A randomized clinical efficacy and safety study."
Dr Nils Lynen et al. has recently published a new study comparing two treatments of painful Achilles tendinopathy: OSTENIL® TENDON injections and extracorporeal shock wave therapy.
Here's a quick quote of the Results and Conclusion:
HA treatment provided a clinically relevant improvement in Achilles midportion tendinopathy. A large superiority of the HA-group, compared to ESWT application, was observed for percent change in pain (VAS) and this superiority was proven to be statistically significant (Mann-Whitney statistic (MW) = 0.7507 with p = 0.0030 lower than required alpha = 0.025 significance level one-sided; Mann-Whitney-U test) at 3 months post-treatment. Similar findings for HA were also observed at 4 weeks (MW = 0.6425, p = 0.0304) and 6 months (MW = 0.7172, p = 0.0018). Advantage of HA treatment was confirmed by VISA-A, CGI and clinical parameters. Ten adverse events, 4 in HA-group and 6 in ESWT-group were reported, but none were classified as serious.
Two peritendinous HA injections showed greater treatment success in Achilles midportion tendinopathy compared to standard ESWT.
The full abstract can be viewed here: https://www.ncbi.nlm.nih.gov/pubmed/27639439